Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

• Michel Delforge,
• Marie-Christiane Vekemans,
• Julien Depaus,
• Nathalie Meuleman,
• Ann Van de Velde,
• Isabelle Vande Broek,
• Sophie Vandervennet,
• Sandra Van Hoorenbeeck,
• Evelien Moorkens,
• Danielle Strens,
• Joris Diels,
• Francesca Ghilotti,
• Benjamin Haefliger,
• Sander Dalhuisen,
• William Deraedt,
• Sébastien Anguille

Affiliations

Michel Delforge

1 Universitaire Ziekenhuizen Leuven, Belgium

Marie-Christiane Vekemans

2 Cliniques Universitaires Saint-Luc, Brussels, Belgium

Julien Depaus

3 Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

Nathalie Meuleman

4 Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Ann Van de Velde

5 Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium

Isabelle Vande Broek

7 AZ Nikolaas, Haematology, Sint-Niklaas, Belgium

Sophie Vandervennet

8 Janssen-Cilag NV, Beerse, Belgium

Sandra Van Hoorenbeeck

8 Janssen-Cilag NV, Beerse, Belgium

Evelien Moorkens

8 Janssen-Cilag NV, Beerse, Belgium

Danielle Strens

9 Realidad bvba, Grimbergen, Belgium

Joris Diels

10 Janssen Pharmaceutica NV, Beerse, Belgium

Francesca Ghilotti

11 Janssen-Cilag SpA, Cologno Monzese, Italy

Benjamin Haefliger

12 Cilag GmbH International, Zug, Switzerland

Sander Dalhuisen

13 Janssen-Cilag BV, Breda, the Netherlands

William Deraedt

10 Janssen Pharmaceutica NV, Beerse, Belgium

Sébastien Anguille

5 Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium